envelop
glycoprotein
b
gb
play
critic
role
viru
entri
host
cell
neutral
antibodi
therefor
potenti
prevent
viru
entri
target
cell
celltocel
spread
infect
present
studi
focus
select
neutral
singlechain
fv
scfv
antibodi
phagedisplay
nonimmun
human
scfv
antibodi
librari
gb
enrich
specif
scfv
two
phage
antibodi
isol
amino
acid
residu
deriv
ntermin
part
gb
use
pan
techniqu
two
scfv
scfvgb
scfvgb
frequenc
obtain
scfv
clone
perform
pcr
mvai
fingerprint
phage
elisa
analysi
gb
gb
scfv
demonstr
high
reactiv
gb
peptid
neutral
assay
scfvgb
scfvgb
repres
neutral
effect
respect
upon
enhanc
neutral
effect
antibodi
consid
new
potenti
altern
treatment
prophylaxi
infect
herp
simplex
viru
hsv
type
remain
signific
pathogen
mani
peopl
adult
popul
around
world
report
infect
viru
tend
nerv
establish
longterm
latent
infect
nervou
system
certain
peopl
recurr
infect
occur
trigemin
ganglia
follow
period
reactiv
latent
viru
viru
caus
varieti
diseas
spectrum
sever
includ
cold
sore
fever
blister
conjunctiv
corneal
lesion
pneumonia
meningoenceph
immunocompromis
individu
antivir
drug
abl
reduc
viral
infect
consid
efficaci
treatment
howev
viru
resist
agent
increas
sever
glycoprotein
play
critic
role
viru
entri
mammalian
cell
celltocel
spread
includ
gb
gd
ghgl
first
stage
establish
infect
lowaffin
revers
attach
viru
cell
surfac
mediat
gb
bind
surfac
heparin
sulphat
proteoglycan
hspg
next
stage
gd
interact
one
multipl
potenti
entri
receptor
nectin
heparan
sulphat
herpesviru
entri
mediat
hvem
follow
gd
attach
one
receptor
undergo
conform
chang
phindepend
fusion
activ
multiglycoprotein
complex
involv
gb
gd
gh
gl
occur
format
neutral
antibodi
reduc
sever
infect
high
level
neutral
antibodi
may
inhibit
spread
viremia
among
glycoprotein
gb
conserv
entri
glycoprotein
act
fusion
protein
four
function
region
gb
identifi
monoclon
antibodi
region
includ
initi
residu
ntermin
part
ii
residu
lessdefin
zone
within
domain
ii
iii
residu
domain
v
residu
within
domain
iv
residu
domain
iv
nearbi
domain
iii
gb
elicit
remark
amount
neutral
antibodi
almost
neutral
activ
account
epitop
ntermin
acid
portion
gb
isol
specif
antibodi
antibodi
phage
display
becom
popular
method
recent
year
gener
librari
life
scienc
consist
either
singl
chain
fragment
variabl
scfv
fab
fragment
smallest
antibodi
fragment
scfv
molecul
kda
scfv
antibodi
sever
advantag
term
pharmacokinet
characterist
includ
lower
retent
nontarget
tissu
higher
penetr
target
tissu
lack
induc
human
antimous
antibodi
respons
therefor
human
scfv
antibodi
perform
consider
better
convent
antibodi
molecul
use
therapeut
applic
thu
far
sever
neutral
scfv
antibodi
produc
number
virus
includ
scfv
antibodi
human
immunodefici
viru
type
scfv
human
cytomegaloviru
scfv
influenza
viru
subtyp
inhibit
viral
infect
vitro
nejatollahi
et
al
describ
neutral
scfvphage
antibodi
glycoprotein
neutral
effect
capabl
neutral
inhibit
viru
entri
host
cell
select
two
neutral
antigb
scfv
antibodi
inhibit
cytopath
effect
vero
cell
infect
phage
scfv
display
librari
form
frozen
e
coli
cell
previous
provid
describ
briefli
expand
e
coli
scfv
librari
glycerol
stock
grown
overnight
agarampicillin
plate
trypton
yeast
extract
glucos
nacl
agar
ampicillin
deioniz
water
grown
cell
scrape
ml
broth
incub
h
reach
optic
densiti
one
helper
phage
ad
medium
mix
incub
min
without
shake
follow
shake
min
bacteria
suspens
transfer
ml
conic
tube
centrifug
rpm
min
bacteri
pellet
transfer
ml
broth
contain
ampicillin
kanamycin
cultur
overnight
shake
afterward
cultur
centrifug
rpm
min
supernat
contain
phage
filter
store
procedur
pan
perform
use
human
phage
display
librari
synthet
epitop
apsspgtpgvaaa
gb
isogen
netherland
follow
round
pan
peptid
phosphat
buffer
salin
pb
coat
immunotub
nunc
roskild
denmark
overnight
tube
wash
four
time
pb
block
h
fetal
bovin
serum
fb
skim
milk
pb
tube
wash
four
time
pbstween
four
time
pb
dilut
phage
librari
supernat
pfu
per
ml
equal
volum
block
solut
ad
incub
h
room
temperatur
follow
wash
bound
phage
elut
logphas
e
coli
incub
h
rescu
phage
three
round
pan
perform
peptid
analyz
divers
select
scfv
antibodi
restrict
fragment
length
polymorph
rflp
fingerprint
perform
pcramplifi
scfv
dna
describ
briefli
dna
fingerprint
carri
coloni
fourth
round
pan
scfv
insert
phagemid
amplifi
use
forward
ccatgattacgccaagctttggagcc
revers
cgatctaaagttttgtcgtctttcc
primer
mvai
enzym
roch
diagnost
gmbh
mannheim
germani
digest
product
pcr
h
dna
product
run
agaros
gel
electrophoresi
measur
phage
concentr
phage
rescu
supernat
phage
antibodi
supernat
ad
ml
logphas
e
coli
incub
shake
h
serial
dilut
bacteria
prepar
cultur
onto
plate
count
number
coloni
per
dilut
scfv
coloni
concentr
titer
per
millilit
calcul
reactiv
isol
scfv
clone
peptid
determin
use
phage
elisa
peptid
pb
coat
well
elisa
plate
overnight
wash
well
three
time
pbstween
three
time
pb
three
time
well
block
block
solut
wv
skim
milk
pb
incub
two
h
follow
wash
dilut
phage
rescu
supernat
pfu
ml
block
solut
ad
dilut
phage
supernat
incub
well
room
temperatur
h
wash
well
dilut
antifd
bacteriophag
antibodi
sigma
uk
pb
ad
incub
room
temperatur
h
plate
wash
hrp
conjug
goat
antirabbit
igg
pb
ad
incub
room
temperatur
h
well
wash
stain
use
mgml
abt
sigma
chemic
pool
usa
citrat
buffer
ph
contain
hydrogen
peroxid
dark
room
temperatur
min
absorb
well
read
nm
use
elisa
reader
calcul
scfv
antibodi
patient
lip
lesion
select
isol
neutral
test
confirm
viru
genu
use
guineapig
serum
nih
usa
monoclon
glycoprotein
g
anti
antibodi
vero
cell
atcc
cultur
dmem
medium
supplement
fetal
calf
serum
gibco
australia
vv
sodium
bicarbon
unitsml
penicillin
streptomycin
sulphat
amphotericin
b
gibco
germani
cell
grown
humidifi
air
co
c
h
confluent
activ
scfv
evalu
use
plaqu
reduct
assay
follow
describ
dilut
dmem
sigmaaldrich
germani
pfuml
equal
amount
viru
scfv
phage
rescu
supernat
mix
incub
h
ml
mixtur
ad
well
plate
contain
confluent
vero
cell
perform
triplic
rock
gentli
min
remov
mixtur
dmem
contain
ml
wv
carboxymethyl
cellulos
cmc
supplement
fetal
calf
serum
vv
sodium
bicarbon
unitml
penicillin
streptomycin
sulphat
amphotericin
b
n
naoh
ad
number
micro
plaqu
count
five
day
compar
number
plaqu
seen
viru
control
well
without
scfv
four
round
pan
peptid
gb
clone
randomli
analyz
pcr
confirm
presenc
insert
segment
predict
band
bp
observ
clone
fig
dna
fingerprint
scfv
clone
epitop
gb
four
round
pan
shown
fig
two
pattern
includ
pattern
one
lane
two
frequenc
scfvgb
scfvgb
obtain
pattern
scfv
use
predomin
pattern
investig
reactiv
scfvsphage
antibodi
scfvgb
scfvgb
gb
peptid
produc
posit
elisa
read
significantli
higher
control
unrel
peptid
unrel
scfvphage
antibodi
without
peptid
nm
fig
neutral
capac
scfv
antibodi
evalu
use
percentag
plaqu
reduct
scfvgb
scfvgb
tabl
first
stage
infect
associ
specif
interact
viral
surfac
protein
cellular
protein
lipid
carbohydr
block
neutral
monoclon
antibodi
studi
monoclon
antibodi
mab
map
identifi
domain
domain
vi
crystal
structur
gb
classifi
group
monoclon
antibodi
belong
subgroup
bound
function
region
domain
vi
gb
contain
first
residu
n
terminu
form
epitop
mab
mab
high
neutral
effect
reduc
plaqu
number
vero
cell
n
antibodi
recogn
singl
peptid
span
residu
previous
report
pereira
et
al
map
neutral
epitop
continu
region
aminotermin
half
gb
neutral
antibodi
recogn
residu
precis
peptid
map
mab
reveal
epitop
mab
residu
constitut
therefor
chose
peptid
fragment
apsspgtpgvaaa
amino
acid
residu
immunodomin
epitop
recogn
neutral
monoclon
antibodi
antibodi
display
phage
power
tool
provid
ligand
specif
target
interest
bind
pure
antigen
synthet
peptid
coat
solid
phase
repetit
pan
round
studi
phage
express
scfv
select
gb
epitop
fourth
round
pan
scfvgb
scfvgb
chosen
frequenc
compar
scfvphage
antibodi
fig
antibodi
librari
antigen
screen
sever
way
direct
phage
elisa
indirect
captur
phage
elisa
result
phage
clone
test
use
phage
elisa
determin
whether
scfv
display
phage
specif
peptid
sever
studi
previous
use
method
evalu
specif
antibodi
target
epitop
antigen
instanc
specif
scfv
helicobact
pylori
hepat
b
viru
surfac
antigen
staphylococc
enterotoxin
b
seb
mycobacterium
avium
subsp
paratuberculosi
surfac
protein
certifi
use
phage
elisa
optic
densiti
od
specif
scfv
interest
target
nm
two
fold
higher
neg
control
posit
phage
elisa
confirm
result
reveal
scfvgb
scfvgb
specif
epitop
gb
mean
od
antibodi
nm
two
fold
higher
control
od
fig
plaqu
reduct
assay
use
test
neutral
activ
scfv
antibodi
hitherto
neutral
scfv
antibodi
produc
mani
viral
protein
surfac
glycoprotein
appeal
target
owe
import
role
viru
attach
receptor
host
cell
exampl
antibodi
includ
scfv
ha
haemagglutinin
influenza
viru
subtyp
gb
gh
cytomegaloviru
respiratori
syncyti
viru
rabi
viru
enter
coronaviru
previou
studi
one
recombin
fabphag
antibodi
select
gb
use
pan
fab
isol
capabl
neutral
either
strain
use
alon
nejatollahi
et
al
isol
one
scfvphage
antibodi
scfvgd
glycoprotein
neutral
effect
studi
two
scfvphage
antibodi
scfvgb
scfvgb
could
neutral
viru
neutral
effect
respect
significantli
decreas
cytopath
effect
vero
cell
moreov
scfv
could
inhibit
viru
vitro
use
alon
tabl
requir
dimer
exert
neutral
effect
owe
sever
advantag
singl
chain
antibodi
could
serv
use
tool
antibodybas
therapi
better
penetr
target
tissu
small
size
made
scfv
effect
antibodi
therapeut
applic
especi
viral
antigen
target
develop
select
neutral
antibodi
human
origin
essenti
antibodi
play
major
role
therapeut
agent
central
nervou
system
infect
pneumonia
induc
immunocompromis
individu
addit
neonat
infect
caus
viru
risk
acquisit
neonat
infect
increas
low
matern
antibodi
avid
thu
neutral
antibodi
find
potenti
applic
prevent
neonat
herp
infect
conclus
present
studi
aim
select
scfv
antibodi
phagedisplay
nonimmun
human
scfv
antibodi
librari
gb
two
scfv
scfvgb
scfvgb
frequenc
obtain
scfv
clone
show
neutral
effect
respect
result
encourag
attempt
mainli
genet
engin
promot
develop
scfv
antibodi
preserv
bind
capac
enhanc
neutral
effect
also
futur
studi
warrant
test
neutral
effect
identifi
scfv
antibodi
purifi
phagefre
form
obtain
better
assess
neutral
effect
also
test
doserespons
associ
neutral
effect
scfv
optim
scfv
antibodi
enhanc
neutral
effect
could
also
relev
test
clinic
trial
author
declar
conflict
interest
tabl
percentag
plaqu
reduct
three
plaqu
reduct
assay
experi
scfvsgb
scfvsgb
antibodi
show
reduct
plaqu
number
respect
control
well
contain
antibodi
number
plaqu
mean
reduct
experi
experi
experi
scfvgb
fig
phage
elisa
posit
scfv
phage
clone
gb
peptid
scfvgb
scfvgb
b
od
nm
scfv
significantli
higher
control
unrel
peptid
unrel
scfv
helper
phage
without
peptid
react
specif
gb
peptid
data
present
mean
standard
error
p
b
